IGM Biosciences, a clinical-stage biotech firm, is on a mission to produce Immunoglobulin M (IgM) antibodies that may help fight cancer, infectious diseases, as well as autoimmune and inflammatory diseases. The firm's product line incorporates imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is currently in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). Additionally, IGM Biosciences is spearheading the development of IGM-8444, an IgM antibody in Phase 1a/1b clinical trials to treat patients suffering from solid cancers. The firm's pipeline also includes IGM-7354, an anti-PD-L1 IgM antibody which is currently in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies. Furthermore, it aims to develop IGM-2644, a bispecific T cell engaging IgM antibody that targets CD38 and CD3 proteins to help patients with multiple myeloma, and IGM-2537, which targets CD123 and CD3 proteins to treat patients struggling with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences has teamed up with Genzyme Corporation to produce, develop, manufacture and commercialize IgM antibodies. The firm, which was previously recognized as Palingen, Inc., altered its moniker to IGM Biosciences, Inc. in 2010. The biotech corporation was founded in 1993 and has its headquarters in Mountain View, California.